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Abstract 
 
Objective: To examine the association of comorbid occurrence of diabetes and depression with risk of 
cardiovascular endpoints including cardiovascular mortality, coronary heart disease and stroke.  
 
Research Design and Methods: A systematic review and metaanalysis. We searched 
PUBMED/MEDLINE, Medscape, Cochrane Library, CINAHL, EMBASE and Scopus databases assessing 
cardiac events and mortality associated with depression in diabetes up until 1 December 2018. Pooled 
hazard ratios were calculated using random- effects models.  
 
Results: Nine studies met the inclusion criteria. The combined pooled hazard ratios showed a 
significant association of cardiac events in people with depression and type 2 diabetes, compared to 
those with type 2 diabetes alone. For cardiovascular mortality the pooled hazard ratio was 1.48 (95% 
CI: 1.185, 1.845), p=0.001, for coronary heart disease 1.37 (1.165, 1.605), p<0.001 and for stroke 1.33 
(1.291, 1.369), p<0.001. Heterogeneity was high in the meta-analysis for stroke events (I-squared = 
84.7%) but was lower for coronary heart disease and cardiovascular mortality (15% and 43.4% 
respectively). Meta-regression analyses showed that depression was not significantly associated with 
the study level covariates mean age, duration of diabetes, length of follow-up, BMI, sex and ethnicity 
(p<0.05 for all models).  Only three studies were found that examined the association of depression 
in type 1 diabetes, there was a high degree of heterogeneity and data synthesis was not conducted 
for these studies.  
 
Conclusions: We have demonstrated a 47.9% increase in cardiovascular mortality, 36.8% increase in 
coronary heart disease and 32.9% increase in stroke in people with diabetes and comorbid depression. 
The presence of depression in a person with diabetes should trigger the consideration of evidence-
based therapies for cardiovascular disease prevention irrespective of the baseline risk of 
cardiovascular disease or duration of diabetes.  
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Introduction 
 
Diabetes is a major health challenge, affecting nearly 415 million people globally. This is expected to 
increase to 642 million by 2040 (1), predominately due to the prevalence of sedentary life styles and 
increasing rates of obesity (2).  
 
Diabetes can have significant impact on quality of life and increases social isolation, negatively 
impacting mental health and long-term management of diabetes (3). Current research suggests that 
people with type 2 diabetes are more likely to be depressed, compared to those without, and people 
with depression are more likely to develop diabetes (4-7).   
 
A number of studies have shown that those with diabetes and coexisting depression have higher rates 
of all- cause mortality and cardiovascular (CV) mortality (7-14)   relative to those with no depression. 
In addition, diabetic patients are even more likely to be depressed following major cardiac events, 
which independently results in increased recurrent CHD risk (Milani et al., 1996).  In a meta-analysis 
(8) a 39% increased risk of cardiovascular mortality was found with the presence of depression in 
people with diabetes.  The study however assessed only five studies from 2005-2012. In this present 
study, we aim to update the review and further the nature of the relationship between diabetes and 
co-morbid depression with cardiovascular morbidity and mortality.   
 
Methods 
Data sources and search strategy  
We conducted this literature-based review using a protocol registered in the PROSPERO International 
prospective register of systematic reviews (accessed at www.crd.york.ac.uk/ 
PROSPERO/display_record.asp?ID=CRD42017083968) and in accordance with guidelines of PRISMA. 
We searched PUBMED/MEDLINE, Medscape, Cochrane Library,  CINAHL, EMBASE and Scopus 
databases, for all articles containing the keywords  “diabetes” or “diabetes mellitus”  in combination 
with “depression” or  “depressive disorder”,  combined with “cardiac mortality” or “cardiovascular 
disease” or “macrovascular complications” or “stroke” (titles and abstract). Stroke was included as a 
cardiovascular outcome, and any papers including type 1 diabetes, depression and mortality 
associated with cardiovascular events were also included.  
The computer-based searches combined free text and medical subject headings and combination of 
key words related to depression and diabetes, with results restricted to English language publications. 
We also searched reference lists of selected studies and relevant reviews for additional publications. 
No separate ethical approval was required for the conduct of this study, as any necessary ethical 
approval was obtained for each of the individual studies contributing data to the meta-analysis. 
 
Study selection and eligibility criteria  
We included only observational studies that enrolled adults with diabetes mellitus (either exclusively 
or as a subgroup) and a clinical history of depression that reported data on cardiovascular endpoints, 
all-cause mortality. Observational studies were chosen as these enable the strength of relationships 
between exposures and outcomes to be determined (15).  Studies published from 1 January 1985 to 
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1 December 2018 were included to ensure a relatively consistent diabetes diagnostic criteria was used 
and avoid the earlier WHO 1985 guidelines definition. 
 
Data extraction and quality assessment 
The titles and abstracts of all articles identified by the broad literature search were assessed 
independently by two reviewers (SS and AF). Studies that did not meet the inclusion criteria were 
discarded. Full text of selected articles were retrieved and assessed to determine if they met the 
inclusion criteria. Of the studies that met the inclusion criteria, one author (AF) initially conducted the 
data extraction using a standardized data collection form and a second author (SS) independently 
checked the extracted data with that in the original articles. The quality of the studies were assessed 
independently by both reviewers. Data were extracted on the following characteristics: study title, 
journal name, first author, year, study design and population, length of follow up, sample size, 
assessment method of diabetes, depression and CVD, how outcomes were measured, antidepressants 
treatment and dose, statistical analysis used, and hazard ratio with corresponding 95% CI and 
multivariable adjustment. 
For cohort and case-control studies, study quality was assessed based on the nine-star Newcastle–
Ottawa Scale (NOS) (16) three pre-defined domains: selection of participants (population 
representativeness), comparability (adjustment for confounders), and ascertainment of outcomes of 
interest. The NOS assigns a maximum of four points for selection, two points for comparability, and 
three points for outcome. Nine points on the NOS reflects the highest study quality. For cross-sectional 
studies, quality was evaluated using the NOS modified for cross-sectional studies (17).  
 
Data synthesis and statistical analysis 
Data was extracted from studies identified through the selection process. Most studies reported the 
associations of depression on cardiac events in terms of hazard ratios, although a few studies reported 
odds ratios. As hazard ratios represent instantaneous risk and odds ratios cumulative risk, they should 
not be combined directly in a meta-analysis (18) so only studies reporting hazard ratios were included 
in the data synthesis. Additionally, only hazard ratios comparing patients with type 2 diabetes and 
depression against type 2 diabetes alone were included, whilst studies comparing patients with type 
2 diabetes and depression, against those with neither condition, were excluded. Only three studies 
were found that examined the association of depression in type 1 diabetes, and there was a high 
degree of heterogeneity and therefore data synthesis was not conducted for these studies.  
9 studies reported relevant outcomes to be included in meta-analyses. Three random effects meta-
analyses were run to combine study estimates on cardiovascular mortality, coronary heart disease 
and stroke. Heterogeneity between studies was assessed using the I-squared statistics (19), and 
explored through meta-regression models using study level estimates for mean age, mean duration 
of diabetes, mean follow-up, mean BMI, percent female, and percent white. For all meta-analyses 
models fitted, funnel plots and Egger’s tests were carried out to assess for publication bias (20). All 
tests were two-tailed and p-values of 0.05 or less were considered significant. STATA release 14 (21) 
was used for all statistical analyses. 
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Results 
 
A total of 1700 potentially relevant citations were retrieved from electronic database searches. From 
these, 178 abstracts were assessed for eligibility, and 25 articles were selected for full text review. Of 
these, 16 full texts were excluded (figure 1).  
<figure 1> 
 
Descriptive data synthesis 
 
Overall 9 prospective cohort studies reported relevant outcomes to be included in meta-analyses 
(table 1). In total there were 346,037 people with diabetes and depression, and 614,574 with diabetes 
only. For these studies the follow up periods ranged from 4-20.8 years, with a mean follow up of 8.3 
years. The mean age at baseline was 60.4 years, ranging from 41.3 - 64.3 years. 
 
Studies used different assessment measures for depression. Six studies used self-report measures, 
including the Patient Health Questionnaire-9 (PHQ-9) (22), four-item Center for Epidemiologic Studies 
Depression (CES-D) questionnaire (23), or the General Health Status Questionnaire (GHS) (24). One 
study used the National Institute of Mental Health Diagnostic Interview Schedule- v3 (DIS) (25). Two 
studies defined depression based on administration records of the medical diagnosis of depression. 
No studies reported the effects of antidepressant treatment.  
 
<table 1>  
Data was extracted from studies identified through the selection process. Four studies, comprising 
13,739 individuals with diabetes and including 3,592 (26%) with comorbid depression reported on 
cardiovascular mortality as an outcome.  
 
Five studies, comprising 11,264 individuals with diabetes and including 3,390 (30%) with comorbid 
depression reported on coronary heart disease as an outcome. Two studies reported on 
cardiovascular or coronary heart disease events, such as myocardial infarction, or typical angina. One 
study reported on incident coronary heart disease, defined as the first hospitalisation for/with CHD. 
Two studies reported on macrovascular complications; one study included congestive heart failure 
and coronary artery bypass grafting, and the other study include composite macrovascular outcomes 
such as major coronary artery disease events such as unstable angina.  
 
Three studies, comprising of 945,136 individuals with diabetes and including 342,466 (36%) with 
comorbid depression reported on stroke as an outcome. One study reported stroke events including 
events with symptoms lasting 24 hours with neuroimaging consistent with acute ischemia or 
haemorrhage.  
 
NOS quality scores ranged from 6-9, with six studies (11, 26-30) receiving a score of 8 or higher.  8 
studies reported type 2 diabetes, however one study (27) reported that in their sample, 34 
participants (44.7%) had type 1 diabetes, and 42 (55.3%) had type 2 diabetes. They did not examine 
type 1 and type 2 patient samples separately.  
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Quantitative data synthesis  
 
The combined pooled hazard ratios all showed a significant risk of cardiac events in people with 
depression and type 2 diabetes, compared to those with type 2 diabetes alone. For cardiovascular 
mortality the pooled hazard ratio was 1.48 (95% CI: 1.185, 1.845), p=0.001, for coronary heart disease 
1.37 (1.165, 1.605), p<0.001 and for stroke 1.33 (1.291, 1.369), p<0.001 (figure 2). Heterogeneity was 
high in the meta-analysis for stroke events (I-squared = 84.7%) but was lower for coronary heart 
disease and cardiovascular mortality (15% and 43.4% respectively). Meta-regression analyses showed 
the impact of depression was not significantly associated with the study level covariates mean age, 
duration of diabetes, length of follow-up, BMI, sex and ethnicity (p<0.05 for all models).  The Egger’s 
test and funnel plot indicated no issues with publication bias for both stroke and cardiovascular 
mortality, but was significant for coronary heart disease (p=0.002), although this result appears to be 
influenced by one small statistically significant study. For all three meta-analyses the number of 
studies was small, making the presence of publication bias difficult to assess.      
<figure 2> 
Only two studies reported hazard ratios over a 10 year follow up period. One study (27) found that 
depression significantly accelerated the presentation of CHD over the 10 year period, p <0.01. 
However, another study (11) found there was no significant difference between hazard ratios, 
associated with cardiovascular mortality, between 5 and 10 year follow up periods.  
 
Sensitivity analysis 
 
Although self-report instruments such as the PHQ-9 are well-validated, one study (31) looked at the 
association of depression with long-term mortality in a prospective follow up study, and found a large 
discrepancy in the rates of depression defined by the PHQ-9 and the clinical interview (using specific 
modules from Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 
Revised Third Edition). Another study (32) demonstrated a higher all-cause mortality risk when 
depression was measured by self-reports in people with diabetes, compared to when measured by 
clinical interviews.  Self-reported measures such as the PHQ-9 may measure somatic symptoms of 
other physical health problems or substance misuse, rather than depression, and may therefore 
inflate the relationship between depression and mortality (31).  
 
Two studies (29, 30) reported depression based on administrative records of the medical diagnosis of 
depression, and another study (27) reported depression based on the National Institute of Mental 
Health Diagnostic Interview Schedule- version 3. The clinical opinion of a psychiatrist was recorded as 
equivalent to a standardised psychiatric interview so these studies can be seen as gold standard and 
merged.  
 
We ran a sensitivity analyses comparing studies which reported a more restricted measure of 
depression (clinically diagnosed depression) compared to those who used a self-reported measure. 
For the four studies reporting cardiovascular disease as an outcome, no studies used a self-reported 
measure, so no comparison could be made. For coronary heart disease, 4 studies reported a more 
restricted measure, whilst one study used a self-reported measure. A meta-regression analysis 
comparing effect size by type of depression measure found no statistical difference (p=0.155) (figure 
3). For stroke, two out of the three available studies used a self-reported depressions score, but again 
no difference in the study hazard ratios was found by type of depression measure (p=0.823) (figure 
4). 
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Discussion 
Summary of findings 
In this systematic and meta-analysis of cohort studies we have summarised all available observational 
studies that have assessed the association of the comorbid occurrence of diabetes and depression 
with clinical CVD endpoints. We have demonstrated a 47.9% increase in cardiovascular mortality, 
36.8% increase in coronary heart disease and 32.9% increase in stroke in people with diabetes and 
comorbid depression. Our findings are consistent with previous reviews on this topic. A meta-analysis 
(8), which reviewed five studies from 2005-2012, found that depression was associated with an 
increased risk of all-cause mortality (HR = 1.46, 95% CI = 1.29-1.66), and cardiovascular mortality (HR 
= 1.39, 95% CI = 1.11-1.73) in people with diabetes. Another study (32) also demonstrated an 
increased all-cause mortality risk (HR = 1.76, 95% CI=1.45-2.14,) when depression was measured by 
self-reports in people with diabetes and HR = 1.49, 95% CI=1.15-1.93 when measured by clinical 
interviews. In addition to being an update of the previous reviews, our study focused on cardiovascular 
outcomes which are the leading cause of morbidity and mortality in people with diabetes, 
demonstrating the added burden of depression on mortality on these outcomes. 
 
Interpretation of findings 
The current evidence suggests an associated increased risk of cardiovascular mortality and stroke in 
people with comorbid depression and diabetes.  This may be explained by several behavioural and 
physiological mechanisms. Depressive symptoms, associated with diabetes, are linked to an increase 
in counter regulatory hormones (such as cortisol and catecholamines), affecting insulin resistance and 
susceptibility to obesity (10). An increased risk of cardiovascular mortality is linked to biological 
alterations caused by depression, such as activation of the hypothalamic-pituitary-adrenal axis and 
proinflammatory cytokines, and dysregulation of the sympathic nervous system (8). Depressive 
symptoms are also related to unhealthy behaviours, such as a poor diet sedentary lifestyle, and poor 
adherence to medical treatment, resulting in higher rates of mortality (33).  
 
Implications of findings 
The current findings provide further insight on the increased risk of cardiovascular outcomes in people 
with diabetes and depression. It is therefore imperative that there is an increased focus on 
cardiovascular disease prevention in this group of patients.  
Cardiac rehabilitation and exercise training may also reduce depression, and associated mortality 
rates, in diabetic CHD patients (Milani and Lavie, 1996). However, patients should also be screened 
for psychological risk factors, such as anxiety and hostility. These are involved in the pathogenesis and 
progression of CVD (Lavie et al. 2016), and may influence mortality rates after cardiac rehabilitation 
(Kachur et al., 2016), possibly mediated through depression (De Schutter et al. 2015). Additional 
interventions, such as stress management training, may enhance the benefits of cardiac rehabilitation 
(Lavie et al., 2016).  
In most patients with diabetes of longer duration of more than 10 years, where the condition is 
considered a cardiovascular risk equivalent, and in people with diabetes and high cardiovascular risk, 
guidelines recommend starting statins for cardiovascular disease preventions. In these patients, 
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whether or not they have depression, they would already be getting the best available evidence for 
prevention of any extra cardiovascular risk confirmed by the depression. However, from our findings, 
it could be argued, that the presence of depression in a person with diabetes should trigger the 
consideration of evidence-based therapies for cardiovascular disease prevention irrespective of the 
baseline risk of cardiovascular disease or duration of diabetes.  
Additionally, for clinicians managing depression, the most significant cause of mortally will be suicide 
and rightly, there is usually a focus in addressing suicide risk in these patient. Our findings open up 
and channel of consideration of reducing death in people with comorbid diabetes and depression. 
Clinicians managing depression therefore need to be aware of the presence of diabetes and 
recommend cardiovascular risk prevention to the patients family doctors.  
 
Strengths and limitations 
The main strength of analysis is the comprehensive search strategy which yielded several published 
studies on the topic. Overall, this review involved 346,037 participants with both diabetes and 
depression and evaluated a wide-range of CVD outcomes and their relationships with the diabetes 
and depression. Formal tests demonstrated no evidence of publication bias.   
Our analysis was a limited by lack of data to assess the impact of baseline cardiovascular risk with 
people with diabetes and depression on subsequent cardiovascular outcomes. This makes our 
suggestions for clinical implications less generalizable. Additionally, as the studies included were 
observational, study level confounding factors, not corrected for, could all have affected the results 
and conclusions we are drawing from this meta-analysis.  
No data was available on the effects of antidepressant treatment. A number of studies have found 
that different antidepressant drugs are associated with several potential adverse outcomes, including 
myocardial infarction (34-37), and stroke/ transient ischaemic attack (38). We therefore acknowledge 
possible confounding by antidepressants as a limitation, and associated implications for managing or 
preventing cardiovascular disease.  
Combining data from studies with differing measures of depression is another limitation that should 
be considered, although we ran a sensitivity analysis comparing studies which reported clinically 
diagnosed depression compared to those who used a self-reported measure. It is important to 
acknowledge that in large data sets clinical interviews are prohibitively expensive, and may therefore 
be a limitation in future studies.  
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Figure 1. Flow chart summarising studies selected for review  
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through electronic database 
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on screening titles for inclusion 
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178 abstracts screened for 
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125 abstracts excluded for not 
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25 full text articles assessed for 
eligibility  
16 full texts excluded.  
7 - studies did not report hazard ratios 
6– groups could not be compared for this meta-analysis  
3 - results were reported too heterogeneously to allow 
for data synthesis  
 
 9 studies included in meta- 
analysis  
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Figure 2. Depression as a risk factor for cardiac events and cardiovascular mortality in patients with 
type 2 diabetes  
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Figure 3. Meta-regression comparison of the pooled effect sizes between the two groups was not 
statistically significant for coronary heart disease, p=0.155. 
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Figure 4. Meta-regression comparison of the pooled effect sizes between the two groups was not 
statistically significant for stroke, p=0.823. 
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Table 1. Summary of studies included in the meta-analysis 
 
Study/year Country Sample 
size 
Mean age/ 
years (SD) 
Length of follow up 
(SD) 
Adjustment for covariates 
Bruce, 2016 Australia 1,337 64.9 (14.4) 4 years N/A 
Coleman, 2013 USA 4,128 63.4 (13.4) 10 years Demographic and clinical 
characteristics (including diabetes 
duration, treatment intensity, 
medical co-morbidity and 
hypertension diagnosis) 
Cummings, 2016 USA 22,003 64 5.95 years Depressive symptom and stress 
category, demographic factors, 
social and economic factors and risk 
factors 
 
Lin, 2009 USA 4,184 64 (12.5) 5 years (1.5) Demographic, clinical characteristics, 
health habits and disease control 
measures 
Clouse, 2003 USA 76 41.3 (15.7) Up to 10 years Demographic information, tobacco 
use, presence of hypertension or 
hyperlipidemia, BMI and 
glycosylated haemoglobin 
Lin, 2010 USA 3,723 64.3 (12.5) 20.8 years Demographic characteristics, clinical 
characteristics,  
health habits or self-care behaviours 
that may be affected by depression  
Sullivan, 2012 USA 2,053 62.2 (6.7) 4.67 (1.45) years Demographic, trial and  clinical 
variables 
Novak, 2016 USA 933,211 64 (11) 7 years Demographic, race/ethnicity, 
baseline eGFR, comorbidities at 
baseline, use of statins and 
antihypertensive medications, BMI 
and serum albumin level 
Ting, 2013 Hong Kong  7,835 51.6 7.4 years Demographic and clinical 
characteristics  
  
